Tag: #transplant

Company News: TolerogenixX Reports Positive Phase Ib Data of its Lead Product to Combat Transplant Rejection

– Product shows excellent safety and tolerability

– Enables long-term reduction of standard medications and side effects while maintaining immune tolerance and transplant function

– Findings endorsed by third-party experts

TolerogenixX GmbH, a biopharmaceutical company developing personalized, cellular therapies to combat organ rejection and autoimmune diseases, today announced the publication of positive Phase Ib results of its lead product MIC-Lx in The Journal of Clinical Investigation (https://doi.org/10.1172/JCI133595). Read more…